Is there any cumulative dose for trastuzumab?

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Trastuzumab is a vital targeted therapy for HER2-positive breast cancer.
• Cardiotoxicity is a known limitation, but its mechanism and dose-dependency remain unclear.
• Existing literature lacks definitive cumulative dose information regarding trastuzumab-induced cardiotoxicity.

Observation:

• A case of a breast cancer patient receiving long-term trastuzumab therapy is presented.
• No cardiac issues were observed in the patient for over four years of treatment.
• This observation was made alongside a review of existing literature.

Findings:

• The presented case suggests that long-term trastuzumab administration may not invariably lead to cardiotoxicity.
• Periodic echocardiographic surveillance appears to be a safe management strategy.
• The findings contribute to understanding the safety profile of trastuzumab in clinical practice.

Implications:

• Trastuzumab can be safely administered to breast cancer patients with appropriate cardiac monitoring.
• Further research into the precise mechanisms of trastuzumab cardiotoxicity is warranted.
• This case supports the use of echocardiography for proactive cardiac risk assessment in patients on trastuzumab therapy.